Skip to main content

Dasabuvir / ombitasvir / paritaprevir / ritonavir Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Jun 27, 2022.

Dasabuvir / ombitasvir / paritaprevir / ritonavir is also known as: Viekira Pak, Viekira XR

Dasabuvir / ombitasvir / paritaprevir / ritonavir Pregnancy Warnings

DASABUVIR (alone), OMBITASVIR (alone), PARITAPREVIR/RITONAVIR (in combination): Animal studies have failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy.
-RITONAVIR (alone): Animal studies with have revealed evidence of developmental toxicity in rats (early resorption, decreased fetal body weight, ossification delays, developmental variations) and rabbits (resorptions, decreased litter size, decreased fetal weights) at maternally toxic doses (75 mg/kg/day and 110 mg/kg/day, respectively). In rats given 35 mg/kg/day, the incidence of cryptorchidism was slightly increased. There are no controlled data in human pregnancy; no developmental effects identified in humans exposed to ritonavir during pregnancy and no association with cryptorchidism.

AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

Use of a ribavirin-containing regimen is contraindicated in pregnant women and in the male partners of women who are pregnant.
-According to some authorities: This product should be used during pregnancy only if the benefit outweighs the risk.

AU TGA pregnancy category: B3
US FDA pregnancy category: Not assigned.

Risk summary: No adequate data available on use of this product in pregnant women to inform a drug-related risk.

-If applicable, the manufacturer product information for ribavirin should be consulted regarding use during pregnancy and use in females and males of reproductive potential.

See references

Dasabuvir / ombitasvir / paritaprevir / ritonavir Breastfeeding Warnings

LactMed: If the mother requires this product, it is not a reason to discontinue breastfeeding; some experts recommend against breastfeeding when this product is used with ribavirin.
-According to some authorities: Breastfeeding is not recommended during use of this product and should be discontinued before starting therapy.

Excreted into human milk: Unknown (dasabuvir, ombitasvir, paritaprevir); Yes (ritonavir)
Excreted into animal milk: Yes (dasabuvir, ombitasvir, paritaprevir [and its hydrolysis product M13])

-Dasabuvir, ombitasvir, and paritaprevir have not been studied in nursing mothers receiving treatment for hepatitis C virus infection.
-Developmental and health benefits of breastfeeding should be considered as well as the mother's clinical need for this product.
-The effects in the nursing infant are unknown; potential side effects in the breastfed child due to this product or the mother's underlying condition should be considered.
-The manufacturer product information for ribavirin should be consulted (if applicable).

Amounts of dasabuvir, ombitasvir, and paritaprevir in breast milk are most likely very low as each component is highly bound to maternal plasma proteins.

Measurable levels of ritonavir are excreted in milk and low levels can be found in the blood of some breastfed infants. No side effects have been reported in breastfed infants.

In 1 study, nursing mothers used ritonavir as part of a clinical trial to evaluate maternal-to-child transmission of HIV infection. Doses, dose regimens, and breast milk collection times were not provided. Ritonavir was not detected in any of 60 breast milk samples.

A total of 23 milk samples were obtained (at birth, 1 month, 3 months, and/or 6 months postpartum) from 9 mothers using lopinavir 400 mg plus ritonavir 100 mg twice a day as part of combination antiretroviral therapy. Their breastfed infants had a total of 6 blood samples analyzed at 1 month, 3 months, and/or 6 months postpartum. Milk samples and infant blood samples were collected at about 4.5 hours (range: 3.5 to 6 hours) after the previous maternal dose and about 30 minutes (range: 20 to 60 minutes) after nursing. The ritonavir level in breast milk averaged 79 mcg/L (range: 31 to 193 mcg/L). The ritonavir plasma level in infants averaged 7 mcg/L (range: 0 to 138 mcg/L), which was about 12% (range: 11% to 40%) of the maternal serum level.

Starting at delivery, 30 mothers used zidovudine 300 mg, lamivudine 150 mg, lopinavir 400 mg, and ritonavir 100 mg orally twice a day; they were studied at 6, 12, or 24 weeks postpartum (10 at each time). Infants could breastfeed freely during the study period. On the study day, breast milk samples and maternal and infant plasma samples were collected before the maternal morning dose (about 14.9 hours after the prior evening dose) and 2, 4, and 6 hours after the maternal dose. Detectable quantities (at least 10 mcg/L) of ritonavir were found in 112 of 121 breast milk samples; breast milk level averaged 79 mcg/L over the 6 hours. Ritonavir was undetectable (less than 10 mcg/L) in all of the 115 infant plasma samples.

At 3-hour intervals before cesarean section, 9 women with HIV infection received 3 doses of lopinavir 200 mg, ritonavir 150 mg, zidovudine 300 mg, lamivudine 50 mg; breast milk samples were collected at about 25 hours postpartum. Milk level averaged 240 mcg/L (range: 98 to 402 mcg/L) for ritonavir in the 8 women where it was quantified.

Ritonavir was measured in 117 breastfed (90% exclusive) infants whose mothers were using lopinavir plus ritonavir for HIV infection during pregnancy and postpartum. At 8 and 12 weeks postpartum, none of the infants had detectable ritonavir plasma levels. At 12 weeks postpartum, ritonavir was detectable in hair samples of 91% of infants; concentration averaged 0.15 ng/mg of hair (range: 0.03 to 0.42 ng/mg). According to author interpretation, infant exposure to ritonavir during breastfeeding is negligible.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC (2022):

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC (2022):
  3. National Library of Medicine (US) "Drugs and Lactation Database (LactMed)" (2019):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.